Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP189611.RA2csbK-1s49IFectHFKkr5V785UWgDbCpHHMseXA3Mhs130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP189611.RA2csbK-1s49IFectHFKkr5V785UWgDbCpHHMseXA3Mhs130_assertion type Assertion NP189611.RA2csbK-1s49IFectHFKkr5V785UWgDbCpHHMseXA3Mhs130_head.
- NP189611.RA2csbK-1s49IFectHFKkr5V785UWgDbCpHHMseXA3Mhs130_assertion description "[High-level MAD2 expression was observed in 26.3% (94 of 358 cases), and correlated with male sex (P=0.0002), tumor progression (pT status) (P=0.0009), visceral or parietal pleural invasion (P=0.0151), non-adenocarcinoma, histological classification (P<0.0001), and smoking history (P=0.0022), but not with patient age or lymph node metastasis (pN status).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP189611.RA2csbK-1s49IFectHFKkr5V785UWgDbCpHHMseXA3Mhs130_provenance.
- NP189611.RA2csbK-1s49IFectHFKkr5V785UWgDbCpHHMseXA3Mhs130_assertion evidence source_evidence_literature NP189611.RA2csbK-1s49IFectHFKkr5V785UWgDbCpHHMseXA3Mhs130_provenance.
- NP189611.RA2csbK-1s49IFectHFKkr5V785UWgDbCpHHMseXA3Mhs130_assertion SIO_000772 21376419 NP189611.RA2csbK-1s49IFectHFKkr5V785UWgDbCpHHMseXA3Mhs130_provenance.
- NP189611.RA2csbK-1s49IFectHFKkr5V785UWgDbCpHHMseXA3Mhs130_assertion wasDerivedFrom befree-20140225 NP189611.RA2csbK-1s49IFectHFKkr5V785UWgDbCpHHMseXA3Mhs130_provenance.
- NP189611.RA2csbK-1s49IFectHFKkr5V785UWgDbCpHHMseXA3Mhs130_assertion wasGeneratedBy ECO_0000203 NP189611.RA2csbK-1s49IFectHFKkr5V785UWgDbCpHHMseXA3Mhs130_provenance.